| NCT ID | NCT06801717 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Miami |
| Condition | Rosacea, Papulopustular |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-11-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for combination treatment of radiofrequency microneedling with the 532 nm KTP laser, and (3) identify potential novel therapeutic strategies for the treatment of rosacea.
Eligibility Criteria
Inclusion Criteria: 1. Male or female adult (\>18yo) subjects in general good health 2. Clinical and/or histologic diagnosis of erythematotelangiectatic or papulopustular rosacea. 3. Subject is able to understand and sign informed consent 4. Subject is able to complete the study and comply with study procedures Exclusion Criteria: 1. Patients currently utilizing oxymetazoline or brimonidine. 2. Presence of dermatoses that might interfere with diagnosis as determined by a study investigator 3. Presence of extreme light sensitivity, or conditions pre-disposing to light sensitivity such as but not limited to xeroderma pigmentosum 4. Any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment 5. History of poor wound healing or blood-clotting abnormality 6. History of keloid formation or hypertrophic scarring 7. Hypersensitivity or contraindication to local anesthetics as determined by the principal investigator or other medical professional. 8. Prisoners
Contact & Investigator
Ariel Eber, MD
PRINCIPAL INVESTIGATOR
University of Miami
Frequently Asked Questions
Who can join the NCT06801717 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rosacea, Papulopustular. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06801717 currently recruiting?
Yes, NCT06801717 is actively recruiting participants. Contact the research team at mmuniz@med.miami.edu for enrollment information.
Where is the NCT06801717 trial being conducted?
This trial is being conducted at Miami Beach, United States.
Who is sponsoring the NCT06801717 clinical trial?
NCT06801717 is sponsored by University of Miami. The principal investigator is Ariel Eber, MD at University of Miami. The trial plans to enroll 20 participants.